Compare
Vivos Therapeutics, Inc. vs Nephros Inc vs Profound Medical Corp. vs Sonoma Pharmaceuticals, Inc.
| Latest fiscal year | Vivos Therapeutics, Inc. VVOS | Nephros Inc NEPH | Profound Medical Corp. PROF | Sonoma Pharmaceuticals, Inc. SNOA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $17.44M | $18.79M | $16.10M | $19.53M |
| Revenue growth (YoY) | +16.0% | +32.7% | +50.7% | +36.7% |
| Gross margin | 60.4% | 61.9% | 70.8% | 38.0% |
| Operating margin | -114.1% | 6.1% | -256.3% | -12.6% |
| Net margin | -121.4% | 6.4% | -264.4% | -16.3% |
| Net income | -$21.17M | $1.19M | -$42.57M | -$3.17M |
| EPS (Diluted) | -$2.07 | $0.11 | $1.41 | -$1.89 |
| Operating cash flow | -$15.26M | $1.60M | -$38.21M | -$3.93M |
| Free cash flow | -$17.60M | n/a | -$38.38M | -$4.12M |
| Cash & equivalents | $2.03M | $5.40M | $59.72M | $2.40M |
| Total assets | $25.15M | $13.64M | $77.47M | $13.96M |
| Total liabilities | $26.70M | $3.44M | $11.04M | $10.87M |
| Shareholders' equity | -$1.49M | $10.20M | $66.43M | $3.10M |
| Return on year-end equity | n/a | 11.7% | -64.1% | -102.6% |
| Shares outstanding | 9.29M | 10.64M | 36.29M | 1.80M |
Revenue, most recent five fiscal years
| Fiscal year | Vivos Therapeutics, Inc. | Nephros Inc | Profound Medical Corp. | Sonoma Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $17.44M Ended 2025-12-31 | $18.79M Ended 2025-12-31 | $16.10M Ended 2025-12-31 | $19.53M Ended 2026-03-31 |
| 1 year earlier | $15.03M Ended 2024-12-31 | $14.16M Ended 2024-12-31 | $10.68M Ended 2024-12-31 | $14.29M Ended 2025-03-31 |
| 2 years earlier | $13.80M Ended 2023-12-31 | $14.24M Ended 2023-12-31 | $7.20M Ended 2023-12-31 | $12.73M Ended 2024-03-31 |
| 3 years earlier | $16.02M Ended 2022-12-31 | $9.97M Ended 2022-12-31 | n/a | $13.27M Ended 2023-03-31 |
| 4 years earlier | $16.89M Ended 2021-12-31 | $10.22M Ended 2021-12-31 | n/a | $12.63M Ended 2022-03-31 |